STOCK TITAN
  1. Home
  2. News
  3. SLS

SELLAS Life Sciences Group Inc - SLS STOCK NEWS

Welcome to our dedicated news page for SELLAS Life Sciences Group (Ticker: SLS), a resource for investors and traders seeking the latest updates and insights on SELLAS Life Sciences Group.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SELLAS Life Sciences Group's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SELLAS Life Sciences Group's position in the market.

News
SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Acute Myeloid Leukemia
Rhea-AI Summary
SELLAS Life Sciences receives Orphan Drug Designation for SLS009 in the treatment of acute myeloid leukemia
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.49%
Tags
clinical trial
-
News
GenFleet Starts Phase Ib/II Trial of GFH009 (Highly Selective CDK9 Inhibitor) Treating Patients with Relapsed/Refractory Peripheral T-cell Lymphomas (PTCL)
Rhea-AI Summary
GenFleet Therapeutics announces the dosing of the first subject in a phase Ib/II trial of GFH009, a CDK9 inhibitor, for relapsed/refractory PTCL patients. Preliminary results show promising clinical efficacy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.7%
Tags
clinical trial
-
News
Athersys Director Jane Wasman Appointed Board Chair
Rhea-AI Summary
Athersys, Inc. announces changes to its Board of Directors. Jane Wasman appointed as Board Chair. Her expertise in strategic, operational, and corporate governance matters will be valuable. She is also chair of the board of directors of Sellas Life Sciences and a member of the board of directors of Rigel Pharmaceuticals. Positive for shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.76%
Tags
none
News
SELLAS Announces Positive Topline Data in Lymphoma Cohort from SLS009 Phase 1 Dose-Escalation Trial, Supporting Advancement to Phase 2 Clinical Study; Primary and Secondary Endpoints Met
Rhea-AI Summary
SELLAS Life Sciences announces positive topline data from Phase 1 trial of SLS009 in lymphoma patients. Clinical response rate overall is 14.7%, overall disease control rate is 35.3%, and clinical response rate in PTCL patients is 36.4%. Recommended Phase 2 Dose established at 100 mg once per week. No off-target safety issues observed. Data demonstrates meaningful anti-tumor activity and clinical responses as a monotherapy. SLS009 continues to emerge as a potential treatment for patients with hematologic malignancies. GenFleet Therapeutics plans to advance GFH009 (SLS009) into Phase 2 clinical studies in China for PTCL patients later this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
clinical trial
-
News
SELLAS Life Sciences to Participate in the Cantor Fitzgerald Global Healthcare Conference
Rhea-AI Summary
SELLAS Life Sciences Group, Inc. to participate in Cantor Fitzgerald Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News
SELLAS Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue Without any Modifications
Rhea-AI Summary
SELLAS announces positive review of Phase 3 REGAL clinical trial of galinpepimut-S in AML
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2023 Financial Results
Rhea-AI Summary
SELLAS Life Sciences Group, Inc. (SLS) reports progress in Phase 2a clinical trial of SLS009 in Acute Myeloid Leukemia and on track for Phase 3 REGAL study with interim analysis expected by late 2023/early 2024. The Company also provided a business update and financial results for the quarter ended June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
earnings
-
News
SELLAS Life Sciences Reports Positive Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
clinical trial
-
News
SELLAS Announces First Patient Dosed in Phase 2a Clinical Trial of GFH009 in Acute Myeloid Leukemia
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.24%
Tags
clinical trial
News
SELLAS Life Sciences Announces Abstract Accepted for Presentation at International Gynecologic Cancer Society Annual Meeting
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.82%
Tags
none
Stock SLS logo
SELLAS Life Sciences Group Inc

Nasdaq:SLS

SLS Rankings

#4389 Ranked by Market Cap
#5312 Ranked by Stock Gains
N/A Ranked by Dividends

SLS Stock Data

75.40M
55.63M
0.5%
10.45%
9.37%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Camden

About SLS

σellas life sciences is a healthcare-oriented global group of companies with a unique and innovative vision, which is ambitious, yet clear: to practice the medicine of tomorrow, today. in other words, we incorporate innovation throughout all our activities aiming at breakthroughs that will have a significant impact on the thinking and practicing of healthcare worldwide. our international team of acknowledged scientists, doctors and health professionals along with a seasoned and highly experienced pharmaceutical executive management form the core of σellas. we strive to improve patients' quality of life through developing and commercializing cutting-edge drugs, medical devices and innovative therapies.